Grandeur Peak Global Advisors LLC Sells 31,570 Shares of HealthEquity, Inc. $HQY

Grandeur Peak Global Advisors LLC decreased its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 86.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 4,875 shares of the company’s stock after selling 31,570 shares during the period. Grandeur Peak Global Advisors LLC’s holdings in HealthEquity were worth $440,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Fifth Third Wealth Advisors LLC lifted its position in shares of HealthEquity by 4.2% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 2,872 shares of the company’s stock worth $240,000 after purchasing an additional 116 shares during the period. Truist Financial Corp increased its holdings in HealthEquity by 4.9% during the fourth quarter. Truist Financial Corp now owns 2,537 shares of the company’s stock valued at $232,000 after buying an additional 119 shares during the period. Fiduciary Trust Co increased its holdings in HealthEquity by 3.4% during the third quarter. Fiduciary Trust Co now owns 3,669 shares of the company’s stock valued at $348,000 after buying an additional 120 shares during the period. Larson Financial Group LLC raised its stake in HealthEquity by 24.4% in the third quarter. Larson Financial Group LLC now owns 628 shares of the company’s stock worth $60,000 after buying an additional 123 shares in the last quarter. Finally, Merit Financial Group LLC raised its stake in HealthEquity by 8.9% in the third quarter. Merit Financial Group LLC now owns 2,112 shares of the company’s stock worth $200,000 after buying an additional 172 shares in the last quarter. Institutional investors own 99.55% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on HQY. Wells Fargo & Company set a $111.00 target price on HealthEquity in a research report on Monday, June 1st. Royal Bank Of Canada boosted their price target on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. Telsey Advisory Group set a $111.00 price objective on HealthEquity in a research note on Friday. Citigroup reaffirmed a “market outperform” rating on shares of HealthEquity in a research report on Friday. Finally, Wall Street Zen upgraded HealthEquity from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.93.

HealthEquity Stock Performance

NASDAQ:HQY opened at $96.37 on Monday. HealthEquity, Inc. has a 52 week low of $72.76 and a 52 week high of $107.62. The firm has a 50 day moving average of $98.16 and a 200 day moving average of $87.93. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $7.97 billion, a price-to-earnings ratio of 34.79, a PEG ratio of 1.53 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last announced its earnings results on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.05. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The company had revenue of $350.73 million during the quarter, compared to the consensus estimate of $349.22 million. HealthEquity’s revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, sell-side analysts anticipate that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.

HealthEquity News Roundup

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
• Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
• Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.

Insiders Place Their Bets

In related news, EVP Michael Henry Fiore sold 2,354 shares of the business’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $95.00, for a total transaction of $223,630.00. Following the transaction, the executive vice president directly owned 52,244 shares in the company, valued at $4,963,180. The trade was a 4.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the transaction, the director directly owned 62,395 shares in the company, valued at $6,527,140.95. This represents a 10.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,456 shares of company stock valued at $1,256,664 in the last three months. Insiders own 1.60% of the company’s stock.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.